EMBC — Embecta Corp
NASDAQ · Health Care · Health Care
- Latest Close
- $9.13
- 30-Day Move
- -20.9%
- Market Cap
- $524M
- Shares Outstanding
- 59,220,000
- P/E Ratio
- 3.76
- ROE
- 69.9%
Embecta Corp
A read-only Alphactor snapshot forEmbecta Corp. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$9.13
30-Day Move
-20.9%
Market Cap
$524M
Shares Outstanding
59,220,000
P/E Ratio
3.76
ROE
69.9%
$9.13
-20.9%last 90 delayed daily bars
90D High
$13.45
90D Low
$8.47
Avg Volume
793,428
Gross margin is running at 63.2%, which gives a quick read on operating quality before you open the full model.
Net margin is 12.9%, useful for comparing EMBC against peers in Health Care.
EMBC is down 20.9% over the last 30 trading days shown on this page.
Latest operating income is $76M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$35.10
Rule of 40
13.1%
Latest Close
$9.13
30-Day Move
-20.9%
Market Cap
$524M
Shares Outstanding
59,220,000
P/E Ratio
3.76
ROE
69.9%
ROA
8.8%
Gross Margin
63.2%
Operating Margin
27.5%
Net Margin
12.9%
Debt / Equity
0
Current Ratio
2.41
Dividend Yield
7.0%
Latest Revenue
$261M
Revenue
$261M
Gross Profit
$162M
Operating Income
$76M
Net Income
$44M
Gross Margin
6317.0%
Net Margin
1292.0%
Current Ratio
2.41
Debt / Equity
0.00
Fair Value
$35.10
Upside / Downside
+284.4%
Signal
Undervalued
Implied Growth
-2.9%
DCF
$15.20
EPV
$19.22
EV/Rev
$70.87
Growth Assumption
-1.5%
Discount Rate
9.6%
Terminal Growth
2.0%
Base FCF
$182M
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative growth / decline priced in
Altman Z
1.90
Grey
Piotroski
7
Strong (7-9)
Cash Conversion
2.01x
Rule of 40
13.1%
Concerning
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $1.1B | $369M | $224M | $388M |
| 2023-12-31 | $1.1B | $224M | $70M | $41M |
| 2024-12-31 | $1.1B | $285M | $78M | $20M |
| 2025-12-31 | $1.1B | $296M | $95M | $182M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
After signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 3,546,128 | 0.06% | 2026-02-28 |
| American Century Capital Portfolios, Inc.-SMALL CAP VALUE FUND | 2,920,000 | 0.05% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1,831,834 | 0.03% | 2025-12-31 |
| AMG Funds-AMG Yacktman Fund | 1,750,000 | 0.03% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | 1,432,454 | 0.02% | 2026-02-28 |
| AMG Funds IV-AMG River Road Small Cap Value Fund | 820,637 | 0.01% | 2026-01-31 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 637,581 | 0.01% | 2025-12-31 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 568,490 | 0.01% | 2026-01-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Qube Research & Technologies
Filed 2025-11-14
--
--
BlackRock
Filed 2024-05-10
$123M
--
Vanguard Group
Filed 2025-05-09
$86M
-4.1%
Geode Capital Management
Filed 2025-11-12
$20M
-5.6%
Charles Schwab
Filed 2025-11-10
$15M
+22.7%
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.